
Injectable bromocriptine for alcohol
Substance Use Disorders: Medication-assisted TreatmentLiterature review updated December 2016.
This program was archived June 2026.
Long-acting injectable bromocriptine is an agonist that treats alcohol dependence. Bromocriptine is intended to alleviate withdrawal symptoms by activating dopamine receptors in the brain. Brief psychosocial interventions for alcohol are permitted, but not standardized between centers. Injections are administered monthly for six months.
ALL |
META-ANALYSIS |
CITATIONS |
|
| Meta-Analysis of Program Effects | ||||||||||||
| Outcomes measured | No. of effect sizes | Treatment N | Effect sizes (ES) and standard errors (SE) | Unadjusted effect size (random effects model) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ES | SE | Age | ES | p-value | ||||||||
Alcohol use disorder Clinical diagnosis of alcohol use disorder or symptoms measured on a validated scale. |
2 | 212 | 0.077 | 0.181 | 42 | 0.077 | 0.672 | |||||
Citations Used in the Meta-Analysis
Naranjo, C.A., Dongier, M., & Bremner, K.E. (1997). Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction, 92(8), 969-978.